Register Today for the 2011 Path to Progress
Join the American Brain Tumor Association (ABTA) as we run, walk and strut our way toward a brain tumor cure. Registration is now open for ABTA's 6th annual Path to Progress 5K Run/Walk on Saturday, May 14, 2011, at Soldier Field in Chicago. Proceeds support ABTA's research funding and patient-family programs. Go to www.pathtoprogress.org for more information on creating a team and recruiting members, creating a personal page, fundraising, making a personal donation, volunteering and sponsorship.
ABTA Offers New Advance Care Planning Guide
Advance Care is the process of making choices about your future medical care, and communicating these choices to your family and loved ones. To help you with this process, the ABTA has created a new Advance Care Planning guide, the second in the "Continuum of Care" series (see Palliative Care guide below). This guide explains advance care, the importance of making your medical wishes known to your family and health care team, and the various legal documents called "advance directives" required to ensure that your plans are adhered to. Read Advance Care Planning.
Download ABTA's Revised Pituitary Tumor Brochure
Pituitary tumors originate in the pituitary gland, a bean-sized organ located near the base of the brain. They are the third most common type of brain tumor. The ABTA's revised Pituitary Tumor brochure provides information on tumor causes, symptoms, diagnosis, treatment and follow-up care. Download a free copy of the Pituitary Tumor brochure, along with ABTA's other newly revised publications.
Send Holiday Greetings, Support ABTA
The ABTA is again offering holiday greeting cards - in a variety of styles - to support its research funding and patient-family programs. Personalized imprinting is available on both cards and envelopes, and each card recognizes a donation to ABTA. Read more about the 2010 ABTA Holiday Cards.
ABTA to Host Annual Holiday Kids' Luncheon
Each year, ABTA hosts a holiday luncheon in the Chicago-area for children with a brain tumor diagnosis and their families. The lunch is complimentary, and includes a visit by "Santa Bear" - an NFL Chicago Bear posing as Santa and distributing gifts to each child. This year's event is on Dec. 14, 2010 in Rosemont, Ill. Register your child and family for the luncheon. If you would like to support this event, please contact Allison Simon at email@example.com, or 224-220-2782, for sponsorship information.
Interested in hosting an ABTA Event?
Call us at 1.800.886.1281
Save the Date:
May 14, 2011
ABTA Path to Progress
Other Upcoming November and December
Nov. 13, 2010
The Melanie Dalton Fundraiser
Nov. 25 to Dec. 11, 2010
Throughout the U.S.
Run for Ian
2011 Patient-Family Meetings:
Jan. 25, 2011
Gibbs Regional Cancer Center
Columbia St. Mary ‘s Cancer Center
Nancy N. and J.C. Lewis Cancer & Research Pavillion
ABTA 10th Biennial
July 29-30, 2011
Watch for more information at abta.org
Learn. Share. Support. Connect.
Join the hundreds of patients, family members and friends who are learning, supporting and sharing through ABTA's new social networking site, Connections. Learn more.
November is National Palliative Care and Hospice Month, and National Caregivers Month
The American Brain Tumor Association (ABTA) offers a Palliative Care guide to help patients and family members to navigate the broad range of services that can provide comfort, care and support to individuals living with a brain tumor diagnosis. Read ABTA's Palliative Care guide. In addition, ABTA offers numerous caregiver resources. Read the Care for the Cargiver Corner at the ABTA Web site. Also, read and download the comprehensive Orientation to Caregiving Handbook.
CMS Launches "National Coverage Analysis" on Newly FDA-Approved Cancer Vaccine
The U.S. Centers for Medicare and Medicaid Services (CMS) has launched a "national coverage analysis" of the cancer vaccine Provenge, approved earlier this year by the U.S. Food and Drug Administration (FDA) for the treatment of prostate cancer. The CMS determines which treatments Medicare will cover for seniors. A decision on Provenge could potentially affect other newer, expensive cancer treatments, including those approved and utilized (on and off label) for brain tumors. Read more about the Provenge analysis from CMS. Read the recent Washington Post article: "Review of prostate cancer drug Provenge renews medical cost-benefit debate."
BRAIN TUMOR ORIGINS
New Study: Cell Phones Not Linked to Brain Tumors
A new study appearing in the November issue of Neuro-Oncology found no link between cell phones in the U.S. and brain tumors. Cell phone use has "grown explosively over the past two decades" in the U.S. with 279 million wireless subscribers. In the study, researchers reviewed brain cancer incidence rates using the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) data from 1992 to 2006. With the exception of females, ages 20 to 29, brain tumor incidence declined or remained the same over the 14-year period. For females, ages 20 to 29, there was a "statistically significant" increase in tumors in the frontal lobe of the brain, however, not in the temporal, parietal lobe, or cerebellum - the portions of the brain highly exposed to cell phone radiation. "Overall, these incidence data do not provide support to the view that cellular phone use causes brain cancer." Read a free summary of the research.
Coffee, Tea May Lower Brain Tumor Risk
Drinking a half cup or more of coffee or tea per day is associated with a 34 percent reduction in the risk for glioma, the most common type of brain tumor, according to new research. Read an article on the research from healthfinder.gov. Read a free summary of the research from the American Journal of Clinical Nutrition.
New Technique Delivers Drugs Directly to Brain Tumors
In a new study published in the online Journal of Neurosurgery, bevacizumab (Avastin) was delivered directly to brain tumor cells through a new technique that uses tiny tubes called microcatheters.The study involved 30 participating glioblastoma (GBM) patients, and included patients who had (Group 1) and had not (Group 2) received previous bevacizumab treatments. Using the new procedure, called superselective intraarterial cerebral infusion (SIACI), patients first received the drug mannitol to temporarily open the blood brain barrier, followed by bevacizumab. The procedure was generally "safe and well tolerated" by participating patients, however, tumor reduction was higher in patients who had not previously received bevacizumab. For example, at one month, Group 1 patients had a median reduction in "the area of tumor enhancement" of 34.7 percent, compared to 15.2 percent for Group 2 patients. Read a free summary of the study. Read the recent New York Times article on the research.
Prolonged Chemotherapy May Not be Necessary for Low-Grade Gliomas
A new study in the journal Neuro-Oncology questions the need for prolonged chemotherapy treatment for low-grade gliomas. While previous studies of temozolomide have supported extended chemotherapy for optimal outcome, there are often significant, cumulative side-effects associated with PCV (procarbzine, CCNU, vincristine) treatment. Researchers measured the mean tumor diameter of patients during and after PCV treatment. During treatment, a decrease in the tumor diameter was observed in all patients, however, after treatment stopped, the tumors continued to shrink in 20 of 21 patients. For 60 percent of the patients, the response continued for two years or more after chemotherapy was halted. Read a free summary of the research.
Modified Measles Virus May Halt Medulloblastoma Growth
Medulloblastoma tumors may be susceptible to a modified measles virus. In a new study, five human medulloblastoma cell lines were analyzed for the expression of measles virus receptor CD46. Each sample then received a measles virus injection. All treated cell lines exhibited "significant killing" when infected with the virus, supporting the measles virus as a potentially viable medulloblastoma treatment. Read a free summary of the study appearing in Neuro-oncology.
Molecule Thought to Suppress Tumors May Actually Trigger Growth
The protein epithelial cadherin (E-cadherin), known for its ability to keep cancer cells glued together and thus preventing them from breaking away and metastasizing, may actually trigger tumor development and growth in some glioblastoma brain tumors, according to a new study in the journal PLOS One. As research findings no longer supporter E-cadherin molecule as a definitive tumor suppressor, a better understanding about the role of molecules in brain tumor development is critical, according to study authors. Read a news release on the research from the Mayo Clinic. Read the full study.
FDA Approves Afinitor for Treatment of Rare Brain Tumors
The U.S. Food and Drug Administration (FDA) approved everolimus, marketed as Afinitor, for the treatment of giant cell astrocytoma associated with tuberous sclerosis, a rare genetic disorder. Read a news release on the FDA approval of Afinitor from Novartis. Also this month, a study in the New England Journal of Medicine (NEJM) found that everolimus was associated with a "marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency" and may be a viable alternative to surgery in children and adults with tuberous sclerosis Read a free summary of the research.
ABTA Offers Basic and Translational Grant Opportunities
The ABTA is now accepting applications for its 2011 Basic Research Fellowship and Translational Research Grant programs. Applications are due in the ABTA office no later than January 7, 2011 for Fellowships and Translational research projects to begin July 1, 2011. Basic Research Fellowships are two-year training awards that support the salaries of young researchers entering the field of brain tumor research. Translational Grants are awards that help scientists further develop studies on the cusp of moving from the laboratory into patient testing. Learn more.
Phase I Study of Cellular Immunotherapy for Recurrent Maligant Glioma Now Recruiting
A new study using neural stem cells (NSCs) to treat gliomas is now recruiting participants. The trial utilizes NSCs that have the natural ability to rapidly move toward malignancies, migrating to and distributing themselves within tumors as well as tracking to other tumor sites within the brain. Read a summary of the research from City of Hope. Read more about the clinical trial from the National Institutes of Health (NIH). Read more about clinical trials from ABTA.
The American Brain Tumor Association funds brain tumor research and offers services to patients and family members worldwide. Help us continue these services by supporting ABTA programs. A donation can be made athttp://www.abta.org/index.cfm?contentid=54.
This information is provided by the American Brain Tumor Association, 2720 River Road, Des Plaines, Illinois, 60018.
We can be reached by e-mail at firstname.lastname@example.org, or by phone at 800-886-2282.
Update Email Preferences | Forward to a Friend | Unsubscribe
©2010 American Brain Tumor Association